your market intelligence analyst
Search Results
3 results
Your search is now limited to «Partnerships and Collaborations» expert search.
BioPharma-Reporter 08/15/2019 10:06
Per the agreement, Oncologie will conduct a phase II single-arm, open-label study to evaluate the efficacy and safety of its Bavituximab, an antibody that blocks the activity of phosphatidylserine (PS), with Merck’s, known as MSD outside North America, blockbuster Keytruda (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer.

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities


Strategic Scenarios